Literature DB >> 31956965

Nanotechnology in the arena of cancer immunotherapy.

Md Asadujjaman1, Kwan Hyung Cho2, Dong-Jin Jang3, Joo-Eun Kim4, Jun-Pil Jee5.   

Abstract

Cancer immunotherapy orchestrates the immune system of the human body to fight against cancer cells. By doing this, it has revolutionized cancer treatment. Toxicities arising from dose-limit and low rates of patient response continue to be the major bottlenecks in clinical outcomes. The immune system has a close relationship with tumor. This leads to the combination of nanotechnology and immunotherapy. Nanotechnology can potentiate the efficacy of immunotherapy by enhancing the delivery and retention, and narrowing the toxicity of immunomodulation. In this regard, immunotherapy can combine with nanomedicine to give strategies that could lessen the side effects and improve clinical outcomes in patient populations. In this review, we explore and recapitulate recent advances in nanoparticle-based cancer immunotherapy.

Entities:  

Keywords:  Antibodies; Immunotherapy; Nanomedicine; Nanotechnology; Nucleic acids; Peptides

Year:  2020        PMID: 31956965     DOI: 10.1007/s12272-020-01207-4

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  1 in total

1.  Hyperthermal paclitaxel-bound albumin nanoparticles co-loaded with indocyanine green and hyaluronidase for treating pancreatic cancers.

Authors:  Sung Soo Kim; Hwang Kyung Kim; Hanju Kim; Woo Tak Lee; Eun Seong Lee; Kyung Taek Oh; Han-Gon Choi; Yu Seok Youn
Journal:  Arch Pharm Res       Date:  2020-08-17       Impact factor: 4.946

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.